Medically Ill Hospitalized Patients for COVID-19 THrombosis Extended ProphyLaxis With Rivaroxaban ThErapy: The MICHELLE Trial
Latest Information Update: 12 Apr 2022
Price :
$35 *
At a glance
- Drugs Rivaroxaban (Primary)
- Indications Venous thromboembolism
- Focus Therapeutic Use
- Acronyms MICHELLE
- 27 Mar 2022 Status changed from active, no longer recruiting to completed.
- 13 Sep 2021 New trial record
- 01 Sep 2021 Trial design published in the American Heart Journal.